The mechanism of resistance to anti-VEGF antibody is related to tumor immunity in ovarian cancer patients

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K18640
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Shizuoka Prefectural Hospital Organization
• Principal Investigator: Horikawa Naoki 地方独立行政法人静岡県立病院機構静岡県立総合病院(救急診療部、循環器病診療部、がん診療部、臨床診療部, 臨床診療部, 医長 (60839140)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 抗VEGF抗体 / 進行卵巣癌

Outline of Final Research Achievements

Anti-VEGF antibody (bevacizumab) is broadly used for the treatment with ovarian cancer, but there are individual differences in the curative effect. the mechanism of the difference in curative effect remains unknown. Ever before, it was revealed that the immunosuppression in tumor microenvironment was related to the effect of bevacizumab by the previous studies. Using blood, ascites and tumor specimen of the advanced ovarian cancer case that underwent chemotherapy using bevacizumab,
the relationship between the response of chemotherapy using bevacizumab and immune status in the local immunity was investigated.
Several inflammatory cytokine protein was found to be related to the response of the bevacizumab combination chemotherapy.

Free Research Field

腫瘍免疫

Academic Significance and Societal Importance of the Research Achievements

本研究成果は、炎症性サイトカインを測定することで、進行卵巣癌におけるベバシズマブ併用化学療法が有効な症例を層別化できる可能性、ならびにベバシズマブの治療抵抗性に免疫状態が関連する可能性を示唆している。今後、卵巣癌に対するベバシズマブ抵抗性症例に対し、腫瘍免疫を標的とする新規治療の開発が待たれる。